Alten R, Lorenz H-M, Mariette X, et al. Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2-year results from the real-world ACTION study. EULAR 2017, FRI0245.
Anti-C5a-antilichaam vilobelimab veilig bij ernstige COVID-19
feb 2021 | Pneumonie, Virale infecties